![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.
Lead Product(s): Anacaulase-bcdb
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
NexoBrid (anacaulase-bcdb) is a botanical drug product containing proteolytic enzymes indicated for the removal of eschar in adults with deep partial or full-thickness thermal burns.
Lead Product(s): Anacaulase-bcdb
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2022
Details:
Data published in the Journal of Burn Care & Research for Epicel® (cultured epidermal autografts) showed 83% of patients with posterior burns (mean total body surface area of 56%) had successful engraftment of Epicel after one or two applications.
Lead Product(s): Cultured Epidermal Autograft
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Epicel
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022